Alnylam PharmaceuticalsALNY

• Phase 3Vutrisiran 아밀로이드 심근병증 치료 유효성 임상진행 중A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
  59%
• Phase 3유전성 아밀로이드 다발신경병증 누크레시란 치료 임상모집 중TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
  59%
• Phase 3파티시란 심근병증 동반 아밀로이드증 임상진행 중APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
  45%
• Phase ?파티시란-LNP 임산부 안전성 추적 관찰 프로그램모집 중Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
  59%
• Phase 3아밀로이드 심근병증 대상 Nucresiran 임상모집 중TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
  59%
• Phase 3심혈관 고위험군 난치성 고혈압 치료제 질레베시란 임상모집 중Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  99%
• Phase 1조기 발병 알츠하이머병 환자 대상 ALN-APP 안전성 1상모집 중A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
  62%
• Phase 2뇌 아밀로이드 혈관병증 치료제 ALN-APP 2상 임상모집 중A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
  78%
• Phase 1ALN-HTT02 성인 헌팅턴병 치료 임상모집 중A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
  67%
• Phase 1ALN-6400 유전성 혈관 확장증 치료 임상모집 중A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
  54%
• Phase ?ELEVATE 급성 간성 포르피린증 환자 등록 연구모집 중ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
  59%
• Phase 3부트리시란 아밀로이드 심근병증 3상 임상진행 중HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
  59%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.